ALK positive

Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer - ⁦@JTOonline⁩ (N=46) ⬆️central obesity from 27-47% ➡️ as pts get treated for years, weight gain is a serious AE #lcsm ⁦@ALKPositiveinc⁩ ⁦ https://t.co/FJlfh8BgKv (@Latinamd)

Early breakfast with @ALKPositiveinc discussing the needs of our patients with ALK positive NSCLC #ASCO23 @ASCO @IASLC (@NarjustFlorezMD)

✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “ALK-positive lung cancer: a moving target” by, @DrJaimeLaurel @JessicaJLinMD & #AliceTShaw. Find it here👇 https://t.co/PgDvca9RLc https://t.co/NZcXj7QElT (@NatureCancer)

Resistance mechanisms in ALK fusion-positive lung cancer https://t.co/mjdAblRY0I (@MLPOncoData)

🩸 Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study. Q: With an 18% 12-months VTE incidence, should thromboprophylaxis be recommended upon ALK+ diagnosis? #lcsm https://t.co/Duep8S5c1a (@Tony_Calles)

ALK-positive lung cancer: a moving target https://t.co/4aM3d0zRGI (@AndresFCardonaZ)

Lorlatinib Induces Rapid and Durable Response in Refractory Anaplastic Lymphoma Kinase–Positive Large B-Cell Lymphoma | JCO Precision Oncology https://t.co/eAxXw1WY2y (@VivekSubbiah)

30 yo F with ALK positive NSCLC with 4 BM. Treated with Lorlatinib with excellent response since 9/2022. Oligo persistent left frontal brain met. RX with SRS now? or only if progression? @SamuelChaoMD @GauravMarwahaMD @DrRoyHerbstYale @Mat_Guc @jryckman3 @drdavidpalma (@PhilBlumenfeld)

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC) https://t.co/upV1jYqRkR (@DrViteri)

The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review. https://t.co/csFNo4SWNW #radonc #srs #LCSM in the majority of cases the quality of life must the main target of the treatment strategy. (@FuenteApolo)

🔥NEW REVIEW ARTICLE @NatureCancer “ALK-positive lung cancer: a moving target” – by @JessicaJLinMD @DrJaimeLaurel #AliceShaw. https://t.co/PgDvca9RLc https://t.co/nmxsw9elQF (@NatureCancer)

ALK-positive lung cancer: a moving target | Nature Cancer https://t.co/UPKXMlmk9V (@lindamahj)

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings. @JTOonline DOI 👇🏻 https://t.co/RkoeT3NC14 #nsclc #lcsm #alk #targetedtherapy #rwd (@diegoadiazg)

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings - JTO Clinical and Research Reports https://t.co/TOOSpx1GV9 (@tehfem)

ALK-positive large B-cell lymphoma, a rare B-cell lymphoma expressing ALK https://t.co/V1EyCZl025 (@smbenlazar)

No v, got covid once. Took HCQ prophylactic. Stage 4 lung cancer ALK positive DX 3 years ago. No rad or chemo to date. (@satguy1963)

News in brief: 3-year findings from the CROWN trial confirm the long-term benefits of lorlatinib for treatment-naïve, advanced ALK-positive NSCLC regardless of baseline brain metastases, say @bensolomon1 (@PeterMacCC) @JulienMazieres et al @LancetRespirMed https://t.co/DJ6YyKcCiJ (@MM_Oncology)

ALK-positive large B-cell lymphoma, a rare B-cell lymphoma expressing ALK https://t.co/V1EyCZkscx #DLBCL #lymsm (@smbenlazar)

Efficacy & safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study - The Lancet Respiratory Medicine @bensolomon1 https://t.co/g4yj8Z3cG1 (@VivekSubbiah)

Early View | Haematologica Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma https://t.co/IaYDH2exv9 (@CwynKate)

During a Targeted Oncology case-based roundtable event, Benjamin Levy, MD, discussed the current targeted treatment options that target lung cancers that are positive for ALK rearrangements. @hopkinskimmel @benlevylungdoc https://t.co/gYtz8b0Acl (@TargetedOnc)

Assessment of Alectinib vs Ceritinib in ALK-Positive NSCLC in Phase 2 Trials and Real-world Data https://t.co/d6Ab7XUi0p via @JAMANetworkOpen part of @JAMANetwork (@VivekSubbiah)

Leukemic phase of ALK-positive anaplastic large cell lymphoma | ASH Image Bank | American Society of Hematology https://t.co/7ansdb70DC #ASHImageBank (@smbenlazar)

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) https://t.co/BFljX1kxWD (@tehfem)

Patient-Reported Outcomes From the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive Non-Small Cell Lung Cancer - #LCSM #ALK https://t.co/sUe8ePio8k (@Tony_Calles)

Lorlatinib improved PFS and reduced 12-month cumulative incidence of central nervous system progression compared with crizotinib in patients with advanced ALK-positive NSCLC irrespective of brain metastases at baseline. @bensolomon1 #lcsm https://t.co/3nrbKSsZU0 (@OncLive)

Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell #lungcancer receiving alectinib. Pls. visit ⁦@ESMO_Open⁩ by ⁦@myESMO⁩ https://t.co/WD7MOZ3Qot (@cczielinski)

In patients with advanced ALK-positive NSCLC with brain metastases, first-line lorlatinib induced a 12-month PFS rate of 78% compared with 22% on crizotinib and 78% vs 45%, respectively, for those without. @bensolomon1 #lcsm https://t.co/v9YaXUi0Jh (@OncLive)

Thank you for bringing awareness. Stop the stigma. Anyone with lungs can get lung cancer. I am ALK Positive and because of research I’m still here after 5 years. (@DaisyAlkie)

Research delivers hope. #Research does this by expanding the reach of #PrecisionMedicine for people living with ALK-positive lung cancer. It's why Dr Justin Gainor believes #MoreResearchMoreLife. #LCAM #LCSM #hope @JustinGainor #lungcancer (@ALKLungCancer)

Assessment of Alectinib vs Ceritinib in ALK-Positive NSCLC in Phase 2 Trials and Real-world Data https://t.co/pBY9UPRVDs via @JAMANetworkOpen part of @JAMANetwork (@VivekSubbiah)

#Pembrolizumab monotherapy given in the first-line setting continued to demonstrate durable clinical benefit vs chemotherapy in patients with PD-L1–positive, locally advanced/metastatic #NSCLC without EGFR/ALK alterations. #lcsm | @GilbertodeCas13 @Icesp_ https://t.co/lwMGiYujvo (@TargetedOnc)

An interesting review showed that #Brigatinib effectively treats patients with #ALK-positive non-small cell #lungcancer. https://t.co/o8ca77lXR9 (@Dr_Ivanoncologo)

#TumorBoardTuesday 🔬🧬We kicked off #LungCancerAwarenessMonth with a discussion on ALK positive #NSCLC led by @LeciaSequist! ➡️Here's this week's case 🎀 👉🆓 #CME credit by answering 3 quick❓ ALL CME 🔗: https://t.co/63osUKM6ij CME eval🔗: https://t.co/pM93oTpEm7 (@TumorBoardTues)

1/3 #TumorBoardTuesday Take🏠msgs: #ALK positive #NSCLC ✅5% of NSCLC; esp young, 🚭 ✅Brain mets ~ 30% at dx ✅BEFORE WBRT, get NGS if feasible ✅ALK+ brain mets= responsive to CNS-penetrant TKI 📚We captured @LeciaSequist’s discussion in this moment: https://t.co/T4rbMwLehd (@JohnEbbenMDPhD)

📢 Let’s kick off #LungCancerAwarenessMonth & join #TumorBoardTuesday!! 🫁@LeciaSequist brings us through testing & treating ALK positive #NSCLC 👇🏽Join us!👇🏽 📱Weigh in how YOU’D treat 🧾Bring citations 📊check polls 🔁RT 👩🏻‍⚕️tag peers 🏆🆓CME @MPishvaian @JohnEbbenMDPhD (@TumorBoardTues)

Set a ⏲ to join us here on #TumorBoardTuesday!! 📅 Tues 11.01.22 at 8pm ET 👩🏻‍⚕️ @LeciaSequist 📰 ALK positive #NSCLC #LungCancer 🫁 While we finalize the case, collect FREE #CME (AMA & MOC) 👉🏽 https://t.co/63osUKLysL 👈🏼#OncTwitter (@TumorBoardTues)

What is the probability of ALK IHC positive but not truly ALK disease (false positive IHC)? #lungcancer @JackWestMD @LeciaSequist @APassaroMD (@ajumathew_)

Very informative & worthwhile day for the Mum of a daughter Kay diagnosed with alk positive NSCLC in 2016 aged 17 (@AileenMurgatro1)

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) https://t.co/PVbPEodjYI (@VivekSubbiah)

Great progress in EGFR and ALK positive lung cancer, but a number of emerging clincial scenarios to consider and address posed by @JackWestMD (@gerryhanna)

For PD-L1 positive and EGFR/ALK wild type NSCLC, it is highly possible that neoadjuvant IO is better than adjuvant IO. (@JoeChangMD)